| References: |
Brexpiprazole is a novel D2 dopamine partial agonist.in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently.
in vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder For the detailed information of Brexpiprazole(OPC34712), the solubility of Brexpiprazole(OPC34712) in water, the solubility of Brexpiprazole(OPC34712) in DMSO, the solubility of Brexpiprazole(OPC34712) in PBS buffer, the animal experiment (test) of Brexpiprazole(OPC34712), the cell expriment (test) of Brexpiprazole(OPC34712), the in vivo, in vitro and clinical trial test of Brexpiprazole(OPC34712), the EC50, IC50,and affinity,of Brexpiprazole(OPC34712), For the detailed information of Brexpiprazole(OPC34712), the solubility of Brexpiprazole(OPC34712) in water, the solubility of Brexpiprazole(OPC34712) in DMSO, the solubility of Brexpiprazole(OPC34712) in PBS buffer, the animal experiment (test) of Brexpiprazole(OPC34712), the cell expriment (test) of Brexpiprazole(OPC34712), the in vivo, in vitro and clinical trial test of Brexpiprazole(OPC34712), the EC50, IC50,and affinity,of Brexpiprazole(OPC34712), Please contact DC Chemicals. |
